(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -9.96% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 100.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.5%.
Metagenomi's revenue in 2025 is $30,913,000.On average, 5 Wall Street analysts forecast MGX's revenue for 2025 to be $1,060,658,169, with the lowest MGX revenue forecast at $959,507,222, and the highest MGX revenue forecast at $1,182,722,657. On average, 5 Wall Street analysts forecast MGX's revenue for 2026 to be $834,063,527, with the lowest MGX revenue forecast at $596,092,219, and the highest MGX revenue forecast at $1,379,843,099.
In 2027, MGX is forecast to generate $907,317,238 in revenue, with the lowest revenue forecast at $617,343,680 and the highest revenue forecast at $1,379,843,099.